Compliance and persistence with osteoporosis therapies.

Journal Article (Journal Article;Review)

The US Food and Drug Administration has approved a diverse group of effective osteoporosis therapies. However, these therapies obviously only work when patients with osteoporosis take them. Data from retrospective observational databases have shown poor compliance and persistence with all osteoporosis drugs, particularly oral bisphosphonate therapy. Patients on weekly therapies are more compliant and persistent than those on daily dosing. Data have also shown decreased fracture risk, decreased health care utilization, and lower costs in compliant and persistent patients.

Full Text

Duke Authors

Cited Authors

  • Silverman, SL; Gold, DT

Published Date

  • April 2008

Published In

Volume / Issue

  • 10 / 2

Start / End Page

  • 118 - 122

PubMed ID

  • 18460266

Pubmed Central ID

  • 18460266

Electronic International Standard Serial Number (EISSN)

  • 1534-6307

Digital Object Identifier (DOI)

  • 10.1007/s11926-008-0021-x

Language

  • eng

Conference Location

  • United States